Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States

Next Previous
Trial Profile

A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Rotavirus W179-9 vaccine; Varicella zoster virus vaccine live
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 05 Dec 2023 Status changed from active, no longer recruiting to completed.
  • 03 Jan 2023 Planned End Date changed from 11 Oct 2023 to 10 Oct 2024.
  • 03 Jan 2023 Planned primary completion date changed from 11 Oct 2023 to 10 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top